Phase I clinical trial with a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in dogs with advanced tumors

Cancer Research

Volumn 56, Issue 13, 1996, Pages 3021-3029

  Cesano, Alessandra ^a   Visonneau, Sophie ^a   Jeglum, K Ann ^b   Owen, Jennifer ^a   Wilkinson, Kim ^b   Carner, Kathy ^b   Reese, Laurie ^b   Santoli, Daniela ^a  

^a WISTAR INSTITUTE   (United States)

^b Vet Oncol Serv and Res Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD16 ANTIGEN; CD3 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN A; GAMMA INTERFERON; INTERLEUKIN 2; LYMPHOTOXIN; MAJOR HISTOCOMPATIBILITY ANTIGEN; OKT 3; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DOG; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT REJECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TUMOR;

ANIMALS; DOG DISEASES; DOGS; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0029890635     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. O'Connor, R , Cesano , A , Lange, B , Finan, J., Nowell, P C., Clark, S. C., Raimondi, S. C., Rovera, G , and Santoli, D. Growth factor requirements of childhood acute T lymphoblastic leukemia: correlation between presence of chromosomal abnormalities and ability to grow permanently in vitro. Blood, 77: 1534-1545, 1991.
2. Cesano, A., and Santoli, D. Two unique leukemic T-cell lines endowed with stable cytotoxic function and different spectrum of target reactivity analysis and modulation of their lytic mechanisms. In Vitro Cell Dev. Biol , 28A: 648-656, 1992
3. Cesano, A., and Santoli, D Inducible expression of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-α and interferon-γ in two human cytotoxic leukemic T cell lines. In Vitro Cell. Dev Biol , 28A: 657-662, 1992
4. Cesano, A , Visonneau, S., Clark, S. C., and Santoli, D. Cellular and molecular mechanisms of activation of MHC non-restricted cytotoxic cells by IL-12 J Immunol , 151: 2943-2957, 1993.
5. Cesano, A., Visonneau, S., Cioé, L., Clark, S. C., Rovera, G., and Santoli, D. Reversal of acute myelogeneous leukemia in humanized SCID mice using a novel adoptive transfer approach J. Clin. Invest., 94: 1076-1084, 1994.
6. Cesano, A., Visonneau, S., and Santoli, D. Treatment of experimental glioblastoma with a human MHC non-restricted cytotoxic T cell line. Cancer Res., 55: 96-101, 1995.
7. Mackinnon, S., Barnett, L., Bourhis, J H., Black, P., Heller, G , and O'Reilly, R. J. Myeloid and lymphoid chimerism after T-cell-depleted bone marrow transplantation: evaluation of conditioning regimens using polymerase chain reaction to amplify human minisatellite regions of genomic DNA. Blood, 21. 3235-3241, 1992
8. Rosales, G., Jeglum, K. A., Obrocka, M., and Steplewski, Z. Cytolytic activity of murine anti-dog lymphoma monoclonal antibodies with canine effector cells and complement. Cell. Immunol., 115: 420-428, 1988.
9. Jeglum, K. A. Chemoimmunotherapy of canine lymphoma with adjuvant canine monoclonal antibody 231 In: K A. Jeglum and R. C. Rosenthal (eds ), The Veterinary Clinics in North America. Small Animal Practice: Controversies in Clinical Oncology, pp 73-86. Philadelphia: W. B. Saunders, 1996.
10. McEwern, E. G., and Withraw, S J. (eds.). Tumors of the mammary gland, Ed. 2. Small Animal Clinical Oncology, pp. 356-372. Philadelphia: W. B. Sanders, 1996.
11. Cesano, A., Visonneau, S., Cioé, L., Clark, S C., and Santoli, D. Effects of lethal irradiation and cyclosporin A treatment on the growth and tumoricidal activity of a T cell clone potentially useful in cancer therapy Cancer Immunol Immunother., 40: 139-151, 1995
12. Margolin, K. A., Rayer, A. A., Hawkins, M. J., Atkins, M. B , Dutcher, J. P., Fisher, R. I., Weiss, G. R., Doroshow, J H., Jaffe, H S , Roper, M., Parkinson, D R , Wiernik, P. H., Creekmore, S. P., and Boldt, D. H Interleukin-2 and lymphokine activated killer cells therapy of solid tumors, analysis of toxicity and management guidelines. J. Clin. Oncol., 7 486-498, 1989
13. Rosentein, M., Ettinghausen, J. E , and Rosenberg, S. A. Extravasation of intravascular fluid mediated by systemic administration of interleukin 2. J. Immunol., 137: 1735-1742, 1986.
14. Damle, N K , Doyle, L. V , Bender, J. R., and Bradley, E C Interleukin-2-activated human lymphocytes exhibit enhanced adhesion to normal vascular endothelial cells and cause their lysis J. Immunol., 138. 1779-1785, 1987.
15. Kotasek, D., Ochoa, A. C., Vercellotti, G. M., Bach, F. H., and Jacob, H. S LAK cell-mediated endothelial injury: a mechanism for capillary leak syndrome in patients treated with LAK cells and IL-2 Clin. Res., 35: 660A, 1987.
16. Huang, C. M., Elin, R. J., Ruddel, M., Silva, C., Lotze, M. T., and Rosenberg, S. A. Changes in laboratory results for cancer patients treated with interleukin 2. Clin. Chem , 36: 431-434, 1990
17. Boldt, D H , Mills, B J., Gemlo, B T., Holden, H , Mier, J , Pajetta, E , McMannis, J. D., Escobedo, L V , Sniecinski, I , Rayer, A. A., Hawkins, M. J., Atkins, M B., Ciobanu, N., and Ellis, T. M Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans. Cancer Res., 48. 4409-4416, 1988.
18. Paciucci, P. A , Holland, J. H , Glidewell, O , and Odchimar, R Recombinant interleukin-2 by continuous infusion and adoptive transfer of recombinant interleukin-2 activated cells in patients with advanced cancer. J Clin. Oncol., 7. 869-878, 1989.
19. Hammond, W. P. Purified recombinant human granulocyte-macrophage-colony-stimulating factor stimulates granulocytes in canine cyclic hematopoiesis. Blood, 62 (Suppl.): 165, 1986.
20. Rosenberg, S A In. V. T. DeVita, S. Hellman, and S A. Rosenberg (eds ), Biologic Therapy of Cancer, Ed 2, pp 487-506. Philadelphia: J. B. Lippincott Co., 1995.
21. Blay, J-Y , Favrot, M. C , Negirer, S , Combaret, V., Chouaib, S , Mercatello, A., Kaemmerlen, P., Franks, C. R., and Philip, T Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor. Cancer Res., 50. 2371-2374, 1990.
22. Moore, A S , Theilen, G. H . Newell, A. D , Madewell, B. R., and Rudolf, A. R Preclinical study of sequential tumor necrosis factor and interleukin 2 in the treatment of spontaneous canine neoplasms. Cancer Res., 51: 233-238, 1991.